NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.84 +0.03 (+3.70 %) (As of 12/16/2018 04:00 PM ET)Previous Close$0.84Today's Range$0.7801 - $0.8452-Week Range$0.78 - $1.93Volume18,810 shsAverage Volume82,643 shsMarket Capitalization$10.50 millionP/E RatioN/ADividend YieldN/ABeta3.25 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. Receive CYCC News and Ratings via Email Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCC Previous Symbol CUSIPN/A Webwww.cyclacel.com Phone908-517-7330 Debt Debt-to-Equity RatioN/A Current Ratio5.16 Quick Ratio5.16 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$840,000.00 Price / Sales12.50 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.46 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,470,000.00 Net MarginsN/A Return on Equity-37.02% Return on Assets-30.40% Miscellaneous Employees12 Outstanding Shares12,500,000Market Cap$10.50 million OptionableNot Optionable Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions What is Cyclacel Pharmaceuticals' stock symbol? Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC." When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work? Cyclacel Pharmaceuticals shares reverse split before market open on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) posted its quarterly earnings data on Monday, November, 12th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. View Cyclacel Pharmaceuticals' Earnings History. When is Cyclacel Pharmaceuticals' next earnings date? Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 11th 2019. View Earnings Estimates for Cyclacel Pharmaceuticals. What price target have analysts set for CYCC? 3 equities research analysts have issued twelve-month target prices for Cyclacel Pharmaceuticals' stock. Their forecasts range from $6.25 to $8.00. On average, they expect Cyclacel Pharmaceuticals' stock price to reach $7.0833 in the next twelve months. This suggests a possible upside of 743.3% from the stock's current price. View Analyst Price Targets for Cyclacel Pharmaceuticals. What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals. Has Cyclacel Pharmaceuticals been receiving favorable news coverage? News headlines about CYCC stock have trended somewhat positive on Sunday, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Who are some of Cyclacel Pharmaceuticals' key competitors? Some companies that are related to Cyclacel Pharmaceuticals include Forward Pharma A/S (FWP), Generex Biotechnology (GNBT), Vascular Biogenics (VBLT), Clearside Biomedical (CLSD), GT Biopharma (GTBP), Celsion (CLSN), Helix Biopharma (HBPCF), ProPhase Labs (PRPH), Addex Therapeutics (ADDXF), Oncolytics Biotech (ONCY), Eyenovia (EYEN), Moleculin Biotech (MBRX), X T L Biopharmaceuticals (XTLB), PLx Pharma (PLXP) and Novan (NOVN). Who are Cyclacel Pharmaceuticals' key executives? Cyclacel Pharmaceuticals' management team includes the folowing people: Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 59)Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 57)Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 58)Prof. David Glover Ph.D., FRS FRSE, Chief Scientist (Age 70)Ms. Gill Christie, Director of HR (Age 61) How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cyclacel Pharmaceuticals' stock price today? One share of CYCC stock can currently be purchased for approximately $0.84. How big of a company is Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals has a market capitalization of $10.50 million and generates $840,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 12 workers across the globe. What is Cyclacel Pharmaceuticals' official website? The official website for Cyclacel Pharmaceuticals is http://www.cyclacel.com. How can I contact Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected] MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 103 (Vote Outperform)Underperform Votes: 127 (Vote Underperform)Total Votes: 230MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What is systematic risk?